10-12-1　ⓔ文献

  1. Brambilla E, Travis W: Lung cancer In: Stewart B, Wild C., eds. World Cancer Report 2014. International Agency for Research on Cancer. World Health Organization 2014.

  2. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan)

  3. Siegel RL, Miller KD, et al: Cancer statistics, 2019. CA: a cancer journal for clinicians, 2019; 69: 7–34.

  4. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Ministry of Health, Labour and Welfare, National Cancer Registry).

  5. Monitoring of Cancer Incidence in Japan–Survival 2009–2011 Report (Center for Cancer Control and Information Service, National Cancer Center, 2020).

  6. Matsuda T, Ajiki W, et al, Reserch Group of Population–Based Cancer Registries of Japan: Population–based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol, 2011; 41: 40–51.

  7. Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest, 2003; 123: 21S–49S.

  8. 厚生労働省：平成11–12年度たばこ煙の成分分析について．http://www.mhlw.go.jp/topics/tobacco/houkoku/seibun.html

  9. Wakai K, Development RGft, et al: Tobacco smoking and lung cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Japanese Journal of Clinical Oncology, 2006; 36: 309–324.

  10. Burns DM: Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. Cancer, 2000; 89: 2506–2509.

  11. Katanoda K, Marugame T, et al: Population attributable fraction of mortality associated with tobacco smoking in Japan: a pooled analysis of three large–scale cohort studies. Journal of Epidemiology, 2008; 18: 251–264.

  12. Pleasance ED, Stephens PJ, et al: A small–cell lung cancer genome with complex signatures of tobacco exposure. Nature, 2010; 463: 184.

  13. Peto R, Darby S, et al: Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case–control studies. BMJ, 2000; 321: 323–329.

  14. DeMarini DM: Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutation Research/Reviews in Mutation Research, 2004; 567: 447–474.

  15. Fund WCR, Research AIfC: Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Amer Inst for Cancer Research, 2007.

  16. IARC monographs on the evaluation of carcinogenic risks to humans. IARC, 2004: 1–1452.

  17. Cruz CSD, Tanoue LT, et al: Lung cancer: epidemiology, etiology, and prevention. Clinics in Chest Medicine, 2011; 32:605–644.

  18. Lim SS, Vos T, et al: A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012; 380: 2224–2260.

  19. Takeshima Y, Bennett W, et al: p53 mutations in lung cancers from non-smoking atomic–bomb survivors. The Lancet, 1993; 342: 1520–1521.

  20. Cihak RW, Ishimaru T, et al: Lung cancer at autopsy in a–bomb survivors and controls, Hiroshima and Nagasaki, 1961–1970. I. Autopsy findings and relation to radiation. Cancer, 1974; 33: 1580–1588.

  21. Land CE, Shimosato Y, et al: Radiation–associated lung cancer: a comparison of the histology of lung cancers in uranium miners and survivors of the atomic bombings of Hiroshima and Nagasaki. Radiation research, 1993; 134: 234–243.

  22. Hubbard R, Venn A, et al: Lung cancer and cryptogenic fibrosing alveolitis: a population-based cohort study. American journal of respiratory and critical care medicine, 2000; 161: 5–8.

  23. Brenner DR, Mclaughlin JR, et al: Previous lung diseases and lung cancer risk: a systematic review and meta–analysis. PLoS One, 2011; 6: e17479.

  24. Kusumoto T, Asakura T, et al: Dvelopment of lung cancer in patients with nontuberculous mycobacterial lung disease. Respir Investig, 2019; 57: 157–164.

  25. Sigel K, Makinson A, et al: Lung cancer in persons with HIV. Curr Opin HIV AIDS, 2017; 12: 31–38.

  26. Olivier M, Goldgar DE, et al: Li–Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer research, 2003; 63: 6643–6650.

  27. Truong T, Hung RJ, et al: Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. Journal of the National Cancer Institute, 2010; 102: 959–971.

  28. Spitz MR, Amos CI, et al: The CHRNA5–A3 region on chromosome 15q24–25.1 is a risk factor both for nicotine dependence and for lung cancer. JNCI: Journal of the National Cancer Institute, 2008; 100: 1552–1556.

  29. Bailey–Wilson JE, Amos CI, et al: A major lung cancer susceptibility locus maps to chromosome 6q23–25. The American Journal of Human Genetics, 2004; 75: 460–474.

  30. Lynch J, Bell DW, et al: Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small–Cell Lung Cancer to Gefitinib. the New England Journal of Medicine, 2004; 350: 2129–2139.

  31. Paez JG, Janne PA, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004; 304: 1497–1500.

  32. Westra WH, Baas IO, et al: K–ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer research, 1996; 56: 2224–2228.

  33. Harris CC: 1995 Deichmann Lecture—p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicology letters, 1995; 82: 1–7.

  34. Travis WD, Brambilla E, et al: The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015; 10: 1243–1260.

  35. Travis WD, Brambilla E, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc, 2011; 8: 381–385.

  36. Mukhopadhyay S, Katzenstein AL: Subclassification of non–small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF–1, napsin A, p63, and CK5/6. Am J Surg Pathol, 2011; 35:15–25.

  37. Mitsudomi T, Morita S, et al: Gefitinib versus cisplatin plus docetaxel in patients with non–small–cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology, 2010; 11:121–128.

  38. Maemondo M, Inoue A, et al: Gefitinib or chemotherapy for non–small–cell lung cancer with mutated EGFR. N Engl J Med, 2010; 362: 2380–2388.

  39. Zhou C, Wu YL, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non–small–cell lung cancer (OPTIMAL, CTONG–0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology, 2011; 12: 735–742.

  40. Rosell R, Carcereny E, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non–small–cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology, 2012; 13: 239–246.

  41. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013; 31: 3327–3334.

  42. Solomon BJ, Mok T, et al: First–line crizotinib versus chemotherapy in ALK–positive lung cancer. N Engl J Med, 2014; 371: 2167–2177.

  43. Wu YL, Lu S, et al: Results of PROFILE 1029, a Phase III Comparison of First–Line Crizotinib versus Chemotherapy in East Asian Patients with ALK–Positive Advanced Non–Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018; 13: 1539–1548.

  44. Planchard D, Besse B, et al: Dabrafenib plus trametinib in patients with previously treated BRAF (V600E)–mutant metastatic non–small cell lung cancer: an open–label, multicentre phase 2 trial. The Lancet Oncology, 2016; 17: 984–993.

  45. Planchard D, Kim TM, et al: Dabrafenib in patients with BRAF (V600E)-positive advanced non–small–cell lung cancer: a single–arm, multicentre, open–label, phase 2 trial. The Lancet Oncology, 2016; 17: 642–650.

  46. Drilon A, Siena S, et al: Safety and Antitumor Activity of the Multitargeted Pan–TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA–372–001 and STARTRK–1). Cancer discovery, 2017; 7: 400–409.

  47. Nonaka D: A study of DeltaNp63 expression in lung non–small cell carcinomas. Am J Surg Pathol, 2012; 36: 895-899.

  48. Rekhtman N, Tafe LJ, et al: Distinct profile of driver mutations and clinical features in immunomarker–defined subsets of pulmonary large–cell carcinoma. Mod Pathol, 2013; 26: 511–522.

  49. George J, Lim JS, et al: Comprehensive genomic profiles of small cell cancer. Nature, 2015; 524: 47.

  50. Hage R, de la Riviere AB, et al: Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol, 2003; 10: 697–704.

  51. Caplin ME, Baudin E, et al: Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 2015; 26: 1604–1620.

  52. Travis WD, Linnoila RI, et al: Neuroendocrine tumors of the lung with proposed criteria for large–cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol, 1991; 15: 529–553.

  53. Mochizuki T, Ishii G, et al: Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases. Am J Surg Pathol, 2008; 32: 1727–1735.

  54. Chang YL, Lee YC, et al: Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer, 2001; 34: 91–97.

  55. Beasley MB, Brambilla E, et al: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol, 2005; 40: 90–97.

  56. Salminen US: Pulmonary hamartoma. A clinical study of 77 cases in a 21–year period and review of literature. Eur J Cardiothorac Surg, 1990; 4: 15–18.

  57. Tanno S, Ohsaki Y, et al: [A case of pulmonary hamartoma and sclerosing hemangioma in the same lung]. Nihon Kokyuki Gakkai Zasshi, 2003; 41: 112–116.

  58. 日本肺癌学会：肺癌取扱規約 第8版，金原出版，2017.

  59. Nakamura H, Kawasaki N, et al: Survival following lobectomy vs limited resection for stage I lung cancer: a meta–analysis. Br J Cancer, 2005; 92: 1033–1037.

  60. Sawabata N, Miyaoka E, et al: Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011; 6: 1229–1235.

  61. Hamada C, Tsuboi M, et al: Effect of postoperative adjuvant chemotherapy with tegafur–uracil on survival in patients with stage IA non–small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009; 4: 1511–1516.

  62. Ruckdeschel JC: Combined modality therapy of non-small cell lung cancer. Semin Oncol, 1997; 24: 429–439.

  63. Yoshino I, Yoshida S, et al: Surgical outcome of stage IIIA– cN2/pN2 non-small–cell lung cancer patients in Japanese lung cancer registry study in 2004. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012; 7: 850–855.

  64. Rusch VW, Giroux DJ, et al: Induction chemoradiation and surgical resection for superior sulcus non–small–cell lung carcinomas: long–term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007; 25: 313–318.

  65. Kunitoh H, Kato H, et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non–small–cell lung cancers: report of Japan Clinical Oncology Group trial 9806. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008; 26: 644–649.

  66. Auperin A, Le Pechoux C, et al: Meta–analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small–cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010; 28: 2181–2190.

  67. Antonia SJ, Villegas A, et al: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med, 2018; 379: 2342–2350.

  68. Reinfuss M, Glinski B, et al: [Radiotherapy for stage III, inoperable, asymptomatic small cell lung cancer. Final results of a prospective randomized study (240 patients)]. Cancer Radiother, 1999; 3: 475–479.

  69. Yamamoto N, Nakagawa K, et al: Phase III study comparing second–and third–generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non–small–cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol, 2010; 28: 3739–3745.

  70. Segawa Y, Kiura K, et al: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non–small–cell lung cancer: OLCSG 0007. J Clin Oncol, 2010; 28: 3299–3306.

  71. Kris MG, Johnson BE, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA, 2014; 311: 1998–2006.

  72. Reck M, Rodriguez–Abreu D, et al: Updated Analysis of KEYNOTE–024: Pembrolizumab Versus Platinum–Based Chemotherapy for Advanced Non–Small–Cell Lung Cancer With PD–L1 Tumor Proportion Score of 50％ or Greater. J Clin Oncol, 2019; 37: 537–546.

  73. Reck M, Rodriguez–Abreu D, et al: Pembrolizumab versus Chemotherapy for PD–L1–Positive Non–Small–Cell Lung Cancer. N Engl J Med, 2016; 375: 1823–1833.

  74. Frederickson AM, Arndorfer S, et al: Pembrolizumab plus chemotherapy for first–line treatment of metastatic nonsquamous non–small–cell lung cancer: a network meta–analysis. Immunotherapy, 2019; 11: 407–428.

  75. Gandhi L, Garassino MC: Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med, 2018; 379: e18.

  76. Soria JC, Ohe Y, et al: Osimertinib in Untreated EGFR–Mutated Advanced Non–Small–Cell Lung Cancer. N Engl J Med, 2018; 378: 113–125.

  77. Mok TS, Wu YL, et al: Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med, 2017; 376: 629–640.

  78. Hida T, Nokihara H, et al: Alectinib versus crizotinib in patients with ALK–positive non–small–cell lung cancer (J–ALEX): an open-label, randomised phase 3 trial. Lancet, 2017; 390: 29–39.

  79. Hida T, Nakagawa K, et al: Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non–small–cell lung cancer with or without prior crizotinib therapy. Cancer Sci, 2016; 107: 1642–1646.

  80. Shaw AT, Solomon BJ, et al: ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase–Positive Non–Small–Cell Lung Cancer. J Clin Oncol, 2019; 37: 1370–1379.

  81. Solomon BJ, Besse B, et al: Lorlatinib in patients with ALK–positive non–small–cell lung cancer: results from a global phase 2 study. The Lancet Oncology, 2018; 19: 1654–1667.

  82. Kiura K, Imamura F, et al: Phase 3 study of ceritinib vs chemotherapy in ALK–rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND–5): Japanese subset. Jpn J Clin Oncol, 2018; 48: 367–375.

  83. Inoue A, Kobayashi K, et al: First–line gefitinib for patients with advanced non–small–cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol, 2009; 27: 1394–1400.

  84. Iwama E, Goto Y, et al: Alectinib for Patients with ALK Rearrangement-Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017; 12: 1161–1166.

  85. Inoue A, Yoshida K, et al: Characteristics and overall survival of EGFR mutation–positive non–small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Jpn J Clin Oncol, 2016; 46: 462–467.

  86. Inoue M, Miyoshi S, et al: Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. Ann Thorac Surg, 2000; 70: 1615–1619.

  87. Turrisi AT 3rd, Kim K, et al: Twice–daily compared with once–daily thoracic radiotherapy in limited small–cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 1999; 340: 265–271.

  88. Corso CD, Rutter CE, et al: Role of Chemoradiotherapy in Elderly Patients With Limited–Stage Small–Cell Lung Cancer. J Clin Oncol, 2015; 33: 4240–4246.

  89. Auperin A, Arriagada R, et al: Prophylactic cranial irradiation for patients with small–cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med, 1999; 341: 476–484.

  90. Baka S, Califano R, et al: Phase III randomised trial of doxorubicin–based chemotherapy compared with platinum–based chemotherapy in small–cell lung cancer. Br J Cancer, 2008; 99: 442–447.

  91. Noda K, Nishiwaki Y, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small–cell lung cancer. N Engl J Med, 2002; 346: 85–91.

  92. Horn L, Mansfield AS, et al: First–Line Atezolizumab plus Chemotherapy in Extensive–Stage Small–Cell Lung Cancer. N Engl J Med, 2018; 379: 2220–2229.

  93. Okamoto H, Watanabe K, et al: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small–cell lung cancer: JCOG 9702. Br J Cancer, 2007; 97: 162–169.

  94. Souhami RL, Spiro SG, et al: Five–day oral etoposide treatment for advanced small–cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst, 1997; 89: 577–580.

  95. Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small–cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet, 1996; 348: 563–566.

  96. O'Brien ME, Ciuleanu TE, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small–cell lung cancer. J Clin Oncol, 2006; 24: 5441–5447.

  97. Goto K, Ohe Y, et al: Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second–line treatment for patients with sensitive relapsed small–cell lung cancer (JCOG0605): a multicentre, open–label, randomised phase 3 trial. The Lancet Oncology, 2016; 17: 1147–1457.

  98. Jotte R, Conkling P, et al: Randomized phase II trial of single-agent amrubicin or topotecan as second–line treatment in patients with small–cell lung cancer sensitive to first–line platinum–based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011; 29: 287–293.

  99. Horita N, Yamamoto M, et al: Amrubicin for relapsed small–cell lung cancer: a systematic review and meta–analysis of 803 patients. Sci Rep, 2016; 6: 18999.